New drug combo tested to shrink tough breast cancer before surgery
NCT ID NCT02876107
Summary
This study is testing if adding a targeted drug called panitumumab to standard chemotherapy works better than chemotherapy alone before surgery for a fast-growing, hard-to-treat type of breast cancer. It aims to see which combination shrinks the tumor more effectively, potentially leading to less extensive surgery. The trial involves 42 women newly diagnosed with this specific aggressive cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.